Background Dyslipidemia is responsible for more than half of the global ischemic heart
disease (IHD) and more than 4 million deaths annually. Assessing the prevalence of …

Introduction Dyslipidemia is a common public health problem in people living with human
immunodeficiency virus (HIV) who are receiving antiretroviral therapy and increases the risk …

Background Despite its importance as a major risk factor for cardiovascular disease,
dyslipidemia remains poorly characterized in the African population. Objective To assess the …

Background Data on the burden of dyslipidaemia among people with HIV undergoing
antiretroviral therapy (ART) in sub-Saharan Africa are limited and little is known about the …

Introduction There is a growing concern about dyslipidemia among HIV patients. In spite of
this fact, there is limited evidence for the burden of dyslipidemia among HIV-infected …

Background Data on lipid profile abnormalities among patients receiving highly active
antiretroviral treatment in Ethiopia are very limited. The aim of this study was to determine …

Background: Dyslipidemia is a significant risk factor for premature cardiovascular disease.
People infected with human immunodeficiency virus (HIV) have been shown to develop …

Purpose Data on the prevalence of dyslipidaemia and associated risk factors in HIV-infected
patients from sub-Saharan Africa is sparse. We performed a cross-sectional analysis in a …

Background HIV status has commonly been found to affect the serum lipid profile. Objectives
The aim of this study was to determine the effect of HIV infection on lipid metabolism; such …

Metabolic complications and adverse cardiovascular events are emerging comorbidities
afflicting HIV-infected patients. This review summarizes the lipid abnormalities associated …